Yes our therapy will be administered during the later phases when ARDS develops.
There will be no lack of patient for us to treat because:
1. These other earlier stage medicines (antivirals etc) will fail in a not so insignificant proportion of people and our therapy will be needed to treat the hyper-inflammation associated with ARDS, thus saving lives, reducing hospital stays, and as you say it is likely Rem-L will over 12 months improve respiratory function longer term and prevent re-hospitalisations (12 month data due out any time now).
2. Some people do not (or can not) take antivirals etc early enough to prevent the development of ARDS (which our therapy treats).
In short, there will be no lack of COVID patients to treat due to above reasons as they progress to ARDS.
NIH partnering the upcoming trial to provide data to support an Emergency Use Authorisation. This is not surprising because found to reduce death in under 65's in earlier trial and likely many more longer term benefits to be revealed soon.
- Forums
- ASX - By Stock
- Pfizer Covid Pill: Gameover for MSB's treatment
Yes our therapy will be administered during the later phases...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.08 |
Change
-0.018(1.60%) |
Mkt cap ! $1.230B |
Open | High | Low | Value | Volume |
$1.09 | $1.09 | $1.07 | $1.010M | 935.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
23 | 113385 | $1.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.08 | 27513 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
26 | 113689 | 1.075 |
21 | 154610 | 1.070 |
14 | 111483 | 1.065 |
15 | 344837 | 1.060 |
9 | 149627 | 1.055 |
Price($) | Vol. | No. |
---|---|---|
1.080 | 27513 | 6 |
1.085 | 108864 | 16 |
1.090 | 119711 | 10 |
1.095 | 82303 | 9 |
1.100 | 96978 | 14 |
Last trade - 10.56am 11/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online